Belgium-based digital health scale-up FEops has announced that the PREDICT-LAA study demonstrated that its HEARTguide significantly improved efficiency and outcomes of left atrial appendage closure (LAAC) procedures.
According to the company, the study examined procedural efficiency and showed a 15% reduction in the total number of LAAC devices used, as well as a 50% decline in the number of device repositionings.
Go deeper with GlobalData
It also demonstrated a 25% reduction in radiation and contrast medium use, while the procedural time and success without major complications in complete cases were reduced by 20% in the study’s FEops HEARTguide arm.
Furthermore, the trial showed a significant improvement in procedural outcomes with the device, including 40% more complete left atrial appendage (LAA) occlusion with no LAA patency.
The device’s other procedural outcomes included 60% less retraction of the Amplatzer Amulet disc into the LAA and an 80% reduction of device-related thrombus risk.
See Also:
The study’s principal investigator Dr Ole De Backer said: “PREDICT-LAA is the first prospective trial showing that the accuracy of the selection of the LAAC device size and implant position is significantly better when using FEops HEARTguide as compared to standard CT-sizing.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPREDICT-LAA is a multicentre clinical study with 200 patients that are randomised in a 1:1 ratio of standard planning versus cardiac computed tomography (CT)-simulation-based planning of LAAC with the Amplatzer Amulet LAA occluder.
FEops co-founder and CEO Dr Matthieu De Beule said: “In 2022, we obtained FDA clearance for FEops HEARTguide LAAO workflow, we became a global digital health player with more than 6,000 patients analysed in over 300 hospitals in 27 countries and we have now, as the first company ever, randomised controlled clinical trial data evidencing the value of digital twin technology in the cardiovascular space.”
